非小细胞肺癌术后辅助EGFR-TKI的治疗进展

doi:10.3969/j.issn.1006-7795.2016.06.011

首都医科大学学报 ›› 2016, Vol. 37 ›› Issue (6): 773-776.doi: 10.3969/j.issn.1006-7795.2016.06.011

非小细胞肺癌术后辅助EGFR-TKI的治疗进展

姚舒洋, 支修益

首都医科大学宣武医院胸外科首都医科大学肺癌中心, 北京 100053

收稿日期:2016-10-03 出版日期:2016-12-21 发布日期:2016-12-16
通讯作者: 支修益 E-mail:xiuyizhi2015@163.com
基金资助:
首都医科大学临床基础项目（16JL67）

Adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for non-small cell lung cancer

Yao Shuyang, Zhi Xiuyi

Department of Thoracic Surgery, Xuanwu Hospital, Capital Medical University, Lung Cancer Center of Capital Medical University, Beijing 100053, China

Received:2016-10-03 Online:2016-12-21 Published:2016-12-16
Supported by:
This study was supported by Foundation Clinical Research of Capital Medical University (16JL67).

摘要/Abstract

摘要： 早期非小细胞肺癌（non-small cell lung cancer，NSCLC）术后含铂两药的辅助化学药物治疗（以下简称化疗）可以改善患者的生存时间，但是化疗已经进入平台期。大量的随机对照临床试验已经证实有表皮生长因子受体（epidermal growth factor receptor，EGFR）酪氨酸激酶抑制剂（tyrosine kinase inhibitor，TKI）能显著改善EGFR突变NSCLC患者的生存，但其在早期NSCLC中的作用还没有明确。所以本文对近几年EGFR-TKI作为NSCLC的辅助治疗进行了综述。

关键词: 肺癌, 早期, EGFR突变, 辅助治疗, 靶向治疗

Abstract: According to clinical guidelines, cisplatin-based chemotherapy given in adjuvant setting of non-small cell lung cancer (NSCLC) can contribute to the prolongation of survival. However, chemotherapy has reached a therapeutic plateau. It has been confirmed that epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) provided a dramatic response to patients with advanced EGFR-mutant NSCLC. The role of EGFR TKI in adjuvant setting of NSCLC still remains unclear. The purpose of this review is to evaluate the current and available data.

Key words: lung cancer, early stage, EGFR mutation, adjuvant therapy, targeted therapy

中图分类号:

R734.2

姚舒洋, 支修益. 非小细胞肺癌术后辅助EGFR-TKI的治疗进展[J]. 首都医科大学学报, 2016, 37(6): 773-776.

Yao Shuyang, Zhi Xiuyi. Adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for non-small cell lung cancer[J]. Journal of Capital Medical University, 2016, 37(6): 773-776.

参考文献

[1] Chen W, Zheng R, Baade P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[2] Arriagada R, Dunant A, Pignon J P, et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer[J].J Clin Oncol,2010, 28(1): 35-42.
[3] Butts C A, Ding K, Seymour L, et al. Randomized phase Ⅲ trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and Ⅱ non-small-cell lung cancer: updated survival analysis of JBR-10[J]. J Clin Oncol,2010, 28(1): 29-34.
[4] Pignon J P, Tribodet H, Scagliotti G V, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group[J].J Clin Oncol,2008, 26(21): 3552-3559.
[5] Wu Y L, Zhou C, Hu C P,et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial[J].Lancet Oncol,2014, 15(2): 213-222.
[6] Han J Y, Park K, Kim S W,et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung[J]. J Clin Oncol,2012, 30(10): 1122-1128.
[7] Mok T S, Wu Y L, Thongprasert S,et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J]. N Engl J Med,2009, 361(10): 947-957.
[8] Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR[J].N Engl J Med,2010, 362(25): 2380-2388.
[9] Zhou C, Wu Y L, Chen G,et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study[J]. Lancet Oncol,2011, 12(8): 735-742.
[10] Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial[J].Lancet Oncol,2012, 13(3): 239-246.
[11] Yu Z H, Lin S H, Balter P, et al. A comparison of tumor motion characteristics between early stage and locally advanced stage lung cancers[J].Radiother Oncol, 2012, 104(1): 33-38.
[12] Cedres S, Nunez I, Longo M, et al. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC)[J]. Clin Lung Cancer, 2011, 12(3): 172-179.
[13] Dematteo R P, Ballman K V, Antonescu C R, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial[J]. Lancet, 2009, 373(9669): 1097-1104.
[14] Goss G D, O'Callaghan C, Lorimer I,et al. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study[J].J Clin Oncol, 2013, 31(27):3320-3326.
[15] Thatcher N, Chang A, Parikh P,et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)[J]. Lancet, 2005, 366(9496): 1527-1537.
[16] Zhai H, Zhong W, Yang X, et al. Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer[J].Transl Lung Cancer Res, 2015, 4(1): 82-93.
[17] Janjigian Y Y, Park B J, Zakowski M F, et al. Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations[J]. J Thorac Oncol, 2011, 6(3): 569-575.
[18] Pennell N A, Neal J W, Govindan R, et al. SELECT: a multicenter phase Ⅱ trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC[J]. J Clin Oncol, 2014, 32(5S): Abstr7514.
[19] Kelly K, Altorki N K, Eberhardt W E, et al. Adjuvant Erlotinib Versus Placebo in Patients with Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A randomized, double-blind, phase III trial[J]. J Clin Oncol, 33(34):4007-4014.
[20] Feng S, Wang Y, Cai K,et al. Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy[J]. PLoS One, 2015, 10(10): e0140794.
[21] Li N, Ou W, Ye X,et al. Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage ⅢA-N2 non-small cell lung cancer harbouring EGFR mutations: a randomized, phase Ⅱ study[J].Ann Surg Oncol, 2014, 21(6): 2091-2096.
[22] Lv C, An C, Feng Q, et al. A Retrospective Study of Stage I to Ⅲa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?[J]. Clin Lung Cancer, 2015, 16(6): e173-181.
[23] Tada H, Takeda K, Nakagawa K,et al. Vinorelbine plus cisplatin versus gefitinib in resected non-small cell lung cancer haboring activating EGFR mutation (WJOG6410L)[J].Annals of Oncology, 2012,10:23.

非小细胞肺癌术后辅助EGFR-TKI的治疗进展

Adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for non-small cell lung cancer

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨敏, 燕翔, 刘锡娟, 安国, 丁慧荣, 蔡英, 葛会争. 人肺癌细胞原位移植瘤小鼠模型免疫细胞的多色流式细胞术检测方法的建立[J]. 首都医科大学学报, 2023, 44(1): 99-106.
[2]	李荣雪, 张倩, 邢洁, 孙秀静, 李鹏, 焦月, 张澍田. 超声内镜对早期结直肠癌的诊断价值分析[J]. 首都医科大学学报, 2023, 44(1): 126-130.
[3]	王芸, 李文坤, 苏珈仪, 王亚丹, 吴静. 系统免疫炎症指数在早期结直肠癌及癌前病变筛查中的应用价值[J]. 首都医科大学学报, 2022, 43(5): 760-766.
[4]	张静涛, 王欣然, 韩斌如, 强莹, 刘雪琪, 张毅. 老年肺癌患者胸腔镜肺切除术后并发心律失常的临床特征及危险因素分析[J]. 首都医科大学学报, 2022, 43(4): 564-569.
[5]	李雪, 邢洁, 张倩, 李鹏, 吕富靖, 张澍田. 窄带成像技术联合放大内镜JES分型对早期食管癌的诊断价值[J]. 首都医科大学学报, 2022, 43(2): 210-215.
[6]	苏珈仪, 刘春涛, 王铁山, 李文坤, 杨奕, 武珊珊, 李鹏, 吴静. 血清幽门螺杆菌抗体分型检测与胃黏膜病变的相关性[J]. 首都医科大学学报, 2022, 43(2): 216-220.
[7]	任艳萍, 张俊岩, 吴涵, 罗炯, 杨春林, 马辛, 姜玮. 磁惊厥治疗与无抽搐电痉挛治疗抑郁发作的早期疗效及对认知功能的影响[J]. 首都医科大学学报, 2022, 43(2): 239-243.
[8]	姚舒洋, 李小雪, 王淳秀, 张毅. 埃克替尼联合抗血管药物一线治疗EGFR突变晚期肺腺癌的单中心研究[J]. 首都医科大学学报, 2022, 43(2): 289-293.
[9]	孙灿, 邢洁, 张希, 孙秀静, 张澍田. 内镜下黏膜剥离术治疗低位直肠早癌的临床分析[J]. 首都医科大学学报, 2022, 43(1): 34-37.
[10]	马宗慧, 张倩, 邢洁, 朱圣韬, 李鹏, 张澍田, 孙秀静. 早期胃癌内镜下治疗的非治愈性切除率及影响因素[J]. 首都医科大学学报, 2022, 43(1): 17-21.
[11]	谭晓刚, 张毅. 新辅助免疫治疗在可切除非小细胞肺癌中的应用前景[J]. 首都医科大学学报, 2021, 42(5): 862-867.
[12]	王巍伟, 王珊珊, 张曼. Kininogen 1在非小细胞肺癌体液和组织中的表达及临床意义[J]. 首都医科大学学报, 2021, 42(1): 77-82.
[13]	张阳, 罗美, 何鑫, 蒋英, 李卫华, 张雪芳, 王淑珍. 高级别宫颈上皮内瘤变及早期宫颈癌子宫切除术后患者高危型人乳头瘤病毒消退规律及相关因素分析[J]. 首都医科大学学报, 2018, 39(6): 864-870.
[14]	孙秀静, 张倩, 邢洁, 朱敏, 郭俊峰, 曹彬, 朱圣韬, 李鹏, 张澍田. 超声内镜对早期胃癌浸润深度的诊断价值及影响因素分析[J]. 首都医科大学学报, 2018, 39(5): 669-674.
[15]	李胜鳌, 李琦, 曹春婕, 董洪瑜, 李杰, 张秋奂, 王京源, 华海琴, 王志群. 多层螺旋CT低剂量扫描在CT引导下氩氦刀治疗肺癌时的应用价值[J]. 首都医科大学学报, 2018, 39(2): 185-189.